开发一种类似于拉斯的基于多的核酸输送系统,针对EGFR+膀癌细胞,采用层次的方法
Aayush Aayush1, Saloni Darji1, Kiera M Estes1
1Department of Chemistry & Purdue Institute for Cancer Research, Purdue University, Bindley Bioscience Center, West Lafayette, Indiana 47907, United States.
Biomacromolecules
|August 26, 2024
概括
这项研究引入了一种新型的弹性素样多 (ELP) 纳米载体系统,用于高效的核酸 (NA) 输送. 这些可适应的纳米载体有效地向膀瘤,为现有的NA输送方法提供了一个有希望的替代方案.
科学领域:
- 生物技术是生物技术.
- 纳米医学是一种纳米医学.
- 基因工程是一种基因工程.
背景情况:
- 基于核酸 (NA) 的疗法提供了精确的基因控制,但面临着交付挑战.
- 现有的输送系统,如脂质纳米颗粒和病毒载体,在效率,稳定性和免疫性方面都有局限性.
研究的目的:
- 开发一种多功能弹性类聚类 (ELP) 载体系统,以有效地提供NA.
- 创建可适应的纳米载体 (LENNs),以准具有挑战性的生物部位,如膀瘤.
主要方法:
- 采用层次 (LbL) 配方方法制造基于ELP的核酸纳米粒子 (LENNs).
- 在物理上对LENNs进行了表征,并评估了它们在小鼠和人类膀瘤细胞系中的生物性能.
- 评估了膀瘤细胞内的结合,内化和货物释放动力学.
主要成果:
- 在30-60分钟内,LENNs表现出有效的结合和快速内化到膀瘤细胞中.
- 该ELP载体系统成功地将NA载荷 (siRNA到等离子体) 传递到目标细胞.
- 该系统在准能力,货物大小和拆卸动力学方面表现出灵活性.
结论:
- 开发了一种敏捷,可生物制造和可调节的纳米载体,用于NA输送.
- 伦网为当前的NA输送方法提供了一个有希望的替代方案,克服了脂质纳米粒子和病毒载体的局限性.
- 这种可适应的系统具有各种治疗应用的潜力,需要有针对性的遗传物质传递.
相关概念视频
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K


